Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects With Moderate to Severe Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Candesartan cilexetil/nifedipine (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Registrational
- Sponsors Bayer; Bayer HealthCare
- 31 Aug 2018 Biomarkers information updated
- 28 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.